







































MRI = magnetic resonance imaging.
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Introduction
It is estimated that approximately one in nine women will
develop breast cancer in her lifetime. For example, in the
USA it is estimated that 180000 women develop breast
cancer, and approximately 45000 women die of the
disease each year [1]. It has been demonstrated [2] that
the smaller the lesion is at the time of detection, the better
the prognosis. The ability of mammography screening to
reduce breast cancer mortality rates was demonstrated by
several studies performed in the US and Europe [3–5]. As
much as a 23% reduction in breast cancer mortality for
the screened population has been demonstrated. Addi-
tional studies, such as the Breast Cancer Demonstration
Project sponsored by the US National Cancer Institute
and the American Cancer Society in the 1970s [6], also
demonstrated reduction in breast cancer mortality in a
screened population. It is now generally accepted that
careful screening with mammography will reduce the
breast cancer mortality rate in a given population.
Despite the success of mammography screening, mam-
mography does have limitations. Perhaps its most signifi-
cant limitation is the difficulty in detecting masses within
radiographically dense breast [7]. In addition, cancers can
be missed by mammography. Retrospective studies of
breast cancer in which prior mammograms where read as
negative [8–10] showed that the cancer was visible in ret-
rospect in approximately one-third of the cases. In addi-
tion, the relatively low specificity of mammography leads to
many breast biopsies that reveal benign tissue [11].
Over the past 10 years there has been great progress in
our understanding of risk factors for breast cancer. The
use of genetic testing or risk modeling allows women to
be stratified according to risk [12••,13••]. In addition, it has
been suggested that the radiographic density of a
woman’s mammogram may influence her risk for breast
cancer [14••]. High-risk patients develop breast cancer
when they are young and when the sensitivity of mammo-
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graphy is most limited. Risk stratification, coupled with the
limitations of mammography identified above, has driven
an effort to develop more robust techniques for the detec-
tion of breast cancer.
Breast magnetic resonance imaging
The application of MRI to detect breast cancer was first
reported in the 1980s. Use of intrinsic tissue contrast
based on T1 and T2 was shown [15–17] not to be helpful
for the detection and diagnosis of breast cancer. These
early reports did demonstrate that high-quality images
could be obtained from the breast using dedicated
surface coils. In 1989, Kaiser et al [18] and Heywang et al
[19] independently reported on the use of contrast-
enhanced breast MRI to detect breast cancer. The con-
trast agents used in those studies were freely diffusable
gadolinium chelates. These agents are believed to serve
as crude markers for tumor angiogenesis. In addition to
detecting mammographically visible lesions, an important
finding on early studies was that MRI is capable of detect-
ing breast cancers that are not visible by mammography
[20•].
Although there has been great controversy over the details
of breast MRI technique, there are a number of principles
that are uniformly accepted. Breast MRI is best performed
on high field (³1T) systems. The efficacy of breast MRI on
lower field systems (0.2–0.5T) has not been clearly
demonstrated. In addition, it is widely accepted that dedi-
cated breast surface coils are critical to performing suc-
cessful breast MRI. It is also widely accepted that breast
MRI must be performed with the administration of intra-
venous contrast. In order to detect angiogenesis, imaging
must commence immediately after contrast administration.
Carcinoma is identified by its enhancement after contrast
administration. Unfortunately, many benign lesions, includ-
ing fibroadenomas, benign proliferative disease, and atypi-
cal proliferative disease, will also enhance after contrast
administration. Several strategies have been developed for
differentiating benign from malignant enhancing lesions on
breast MRI. These include use of the architecture of the
enhancing lesion, as well as the kinetics of its enhance-
ment (these techniques are reviewed in detail in an
accompanying review by Leach).
Early reports of contrast-enhanced breast MRI [18] sug-
gested that lesions in which contrast arrived rapidly (within
approximately 2 min) and then washed out over the first
5 min probably represent cancer, whereas those lesions
that showed continuous increase in contrast concentration
over a prolonged period of time were more likely to be
benign. Physiologic models of the kinetic response of the
lesion to contrast have been developed in an effort to char-
acterize tumor angiogenesis better. The key parameter pro-
vided by fitting the kinetic response of the lesion to a
physiologic model is the permeability×surface area
product. This was shown [21•] to be an important predictor
of lesion histology. Although there has been some work in
pharmacokinetic modeling of contrast uptake, it is general
clinical practice to consider lesions that demonstrate
washout kinetics to be more suspicious than those that
exhibit persistent enhancement.
Other early reports on breast MRI [22•] stress the use of
the architecture of enhancement to differentiate benign
from malignant enhancing lesions. Enhancement in a
ductal distribution was considered very suspicious for in
situ cancer. The borders of focal regions of enhancement
were very important determinants of likelihood of malig-
nancy, with the more irregular borders being more suspi-
cious for cancer. Several other architectural features, such
as enhancement along the rim (suspicious for cancer) or
nonenhancing internal septations (probably representing a
benign fibroadenoma), were also described. Nunes et al
[23] reported a recursive partitioning-based architectural
interpretation model for breast MRI, which takes into
account many of these architectural features. In a diagnos-
tic population, MRI demonstrated 96% sensitivity and
72% specificity for differentiating benign from malignant
enhancing breast lesions. It is now generally accepted that
a combination of architectural and kinetic features should
be used for differentiating benign from malignant breast
lesions. The use of these features in a diagnostic popula-
tion will have performance similar to that described in the
model reported by Nunes et al [23].
One of the most exciting uses suggested for breast MRI
was in the evaluation of the extent of breast cancer. Harms
et al [20•] reported that additional foci of cancer could be
detected in up to 30% of women who underwent mastec-
tomy for breast cancer. Similar results have been reported
by other investigators [24]. These reports are very signifi-
cant, and they clearly demonstrated the ability of MRI to
detect mammographically and clinically occult breast
cancer. This fact underscored the need for development
of needle guidance systems for MRI, so that MRI-detected
lesions could be sampled.
The development of techniques and equipment to perform
magnetic resonance-guided breast biopsy was the subject
of a meeting of the Federal Multi-Agency Consortium on
Imaging Technologies to Improve Women’s Health, which
was held on May 1, 1997. Two basic approaches have
been described for performing magnetic resonance-
guided breast interventions. The first involves compress-
ing the breast in a grid similar to the alphanumeric grids
that are used for mammographic needle localization pro-
cedures [25,26•]. Lesions can be localized in three dimen-
sions relative to this grid by scanning patients in the
magnet with the grid applied. Needles can then be placed
into the breast outside of the magnet for purposes of







































compatible, nonmagnetic needles that are available for
this purpose. Others have developed interactive breast
biopsy techniques using open magnet systems. Higher
field, open systems such as the General Electric Magnetic
Resonance Intervention system have been shown to be
useful in this regard [27]. The proliferation of higher field,
open systems will make interactive breast biopsy under
magnetic resonance guidance a reality. In addition to
needle localization, core biopsy and vacuum-assisted core
biopsies are currently being performed under magnetic
resonance guidance at centers around the world.
Magnetic resonance imaging in high-risk
populations
Perhaps the most exciting applications of breast MRI for
the detection of breast cancer involve the screening of
high-risk populations. The first attempt at using MRI to
detect cancer in a mammographically and clinically normal
breast was in the setting of women who present with axil-
lary node disease [28••,29]. Several studies have demon-
strated that breast MRI can detect the primary cancer in
women who present with malignant axillary adenopathy
and unknown primary lesion. In a study reported by Orel et
al [29], MRI detected the primary lesion in 85% of women
who presented with positive axillary nodes, and negative
mammography and clinical examinations. Similar results
were reported by Morris et al [28••].
The next reported application of breast MRI in a screening
role was screening of the contralateral breast in women
with breast cancer. The published results of several small
series [30] suggest a 5–10% cancer yield when screen-
ing the contralateral breast at the time of the original pre-
sentation. For example, Dunfee et al [31] detected nine
otherwise occult contralateral cancers with MRI in 92
patients. This is far in excess of the 2–3% incidence of
contralateral breast cancer suggested by the National Sur-
gical Adjuvant Breast and Bowel Project B-14 study
[32,33]. If these early results were confirmed in larger,
more rigorous studies, then this would indicate that MRI
can detect lesions before they become mammographically
or clinically apparent.
There are a number of studies being performed around the
world that are investigating the potential utility of breast
MRI in high-risk populations. In particular, studies are
being performed in the UK, The Netherlands, Germany,
Canada, and in the USA. The principal investigators of
these studies have been organized into a loose consor-
tium under the umbrella of the International Working
Group for Breast MRI. The Working Group Technical
Report [34] contains information on each of these studies.
Patient populations vary from study to study, and the final
results are not yet available. Although each of these
studies is small, they will collectively accrue approximately
6000 women. Efforts are underway to develop a mecha-
nism for collective analysis of data from across these
studies. Some centers have reported interim results.
A high-risk screening study including 1500 women has
been initiated in the UK, funded through the Medical
Research Council and National Health Service [35••]. Eli-
gible patients are below the age of 50 years and either
carry a known breast cancer susceptibility gene or are cal-
culated to have at least a 50% risk of carrying such a
gene. The study is being conducted at 19 centers
throughout the UK. Women will undergo screening evalu-
ations every year for 4 years that consist of both MRI and
mammography. No preliminary results have been reported
for the UK study.
A Canadian study is being performed at Sunnybrook and
Women’s College Health Sciences Center at the Univer-
sity of Toronto [36••]. That pilot study is aimed at accruing
200 high-risk women. Their high-risk criteria include
women who have at least three relatives who had breast
cancer at age less than 50 years or ovarian cancer at any
age. Women also have no previous radiotherapy for breast
cancer. The protocol consists of annual mammography,
ultrasound, and MRI. Clinical breast examination is per-
formed twice each year. Preliminary results have been
reported on 139 women that have been entered into the
study [36••]. To date six cancers have been detected. All
six were detected by MRI. Two each were detected by
clinical breast examination and mammography. Ultrasound
detected three cancers. A combination of clinical breast
examination and mammography would have detected four
cancers. The combination of clinical breast examination,
mammography, and ultrasound would also have detected
four out of the six cancers. Therefore, two of the six
cancers were occult to conventional screening tech-
niques. The largest cancer detected in the study was
1.5cm, while the smallest was 5mm.
A study being performed by the National Expert and Train-
ing Center for Breast Cancer Screening at the University
of Nijmegan in The Netherlands [37••] is considering two
populations of women: women who are at personal risk for
developing breast cancer on the basis of prior biopsy
results; and women in whom familial risk factors for devel-
oping breast cancer have been identified. To date, a total
of 622 women have been recruited into the screening
study, 228 of whom were recruited on the basis of familial
risk criteria. To date, a total of 45 cancers have been
reported across all individuals enroled in the study.
The National Institutes of Health in the USA is funding a
multicenter pilot study that is aimed at screening high-risk
women for breast cancer. The study is expected to recruit
400 women who have a 30% lifetime risk of cancer on the
basis of the Gail or Clause model, or who have at least a
50% chance of carrying a breast cancer susceptibility
Available online http://breast-cancer-research.com/content/3/1/017gene as assessed using the Couch model. Women
undergo screening examinations every year for 2 years
that consist of clinical breast examination, mammography,
and MRI. This study is currently recruiting, and no data
have yet been released.
The most comprehensive report was that of Kuhl et al
[38••]. In that study of 192 patients, of whom 105 had
adequate follow up to determine disease-free status, a
total of nine cancers were discovered through the use of
mammography, mammography + ultrasound, and MRI
screening. Three cancers were detected by mammogra-
phy; mammography + ultrasound detected a total of four
cancers. MRI detected all nine cancers; this included five
cancers that were occult to mammography + ultrasound.
These results, although very preliminary, clearly demon-
strate great potential for MRI in increasing the yield of
screening high-risk women.
Conclusion
Breast MRI is a developing imaging modality that has
shown great promise for the early detection of breast
cancer. Some of the basic principles of technique and
interpretation are beginning to be standardized. Equip-
ment to perform magnetic resonance-guided interventions
is beginning to become available. Early results suggest
that MRI may dramatically improve the yield of screening
certain at-risk populations. However, there has been no
large study to validate the efficacy of MRI as a screening
modality for any population. Continued work needs to be
performed to establish clearly the role for breast MRI in
early detection of breast cancer.
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